与黑色素瘤BRAF/NRAS亚型相关的遗传性基因变异
在基因、环境与黑色素瘤研究中,1223例欧洲裔参与者的初发侵袭性原发性黑色素瘤接受了BRAF/NRAS突变筛查,并对47个低外显率黑色素瘤风险单核苷酸多态性进行胚系基因分型。IRF4 rs12203592*T与BRAF V600E相关(OR=0.59,95%CI=0.43-0.79),PLA2G6 rs132985*T与BRAF V600E相关(OR=1.32,95%CI=1.05-1.67)。作者认为IRF4和PLA2G6遗传基因型可能影响黑色素瘤BRAF/NRAS亚型的发生。
要点
- IRF4 rs12203592*T与BRAF V600E相关,OR=0.59(95%CI=0.43-0.79)。
- PLA2G6 rs132985*T与BRAF V600E相关,OR=1.32(95%CI=1.05-1.67),与BRAF other相关,OR=1.82(95%CI=1.11-2.98)。
- 作者认为IRF4和PLA2G6遗传基因型可能影响黑色素瘤BRAF/NRAS亚型发生。
核心结论
- IRF4和PLA2G6遗传基因型可能影响黑色素瘤BRAF/NRAS亚型的发生。
研究设计与样本
- 基因、环境与黑色素瘤研究纳入1223名欧洲裔参与者,对其初发侵袭性原发性黑色素瘤筛查BRAF/NRAS突变,并对47个低外显率黑色素瘤风险单核苷酸多态性进行胚系基因分型。
- 采用多项logistic回归,同时分析每个单核苷酸多态性与BRAF V600E、BRAF V600K、BRAF other及NRAS+黑色素瘤的关系,参照组为BRAF-/NRAS-黑色素瘤,并校正研究特征。
主要发现
- IRF4 rs12203592*T与BRAF V600E相关(OR=0.59,95%CI=0.43-0.79),与BRAF V600K相关(OR=0.65,95%CI=0.41-1.03),但与BRAF other及NRAS+黑色素瘤无关。
- IRF4 rs12203592的病因异质性整体检验Pglobal=0.001,通过错误发现检验Pglobal=0.0026。
- PLA2G6 rs132985*T与BRAF V600E相关(OR=1.32,95%CI=1.05-1.67),与BRAF other相关(OR=1.82,95%CI=1.11-2.98),但与BRAF V600K及NRAS+黑色素瘤无关。
- PLA2G6 rs132985的病因异质性检验Pglobal=0.005。
- 校正黑色素瘤风险表型后,IRF4 rs12203592的关联略有减弱;PLA2G6 rs132985的关联独立于表型。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BRAF and NRAS mutations arise early in melanoma development, but their associations with low-penetrance melanoma susceptibility loci remain unknown. In the Genes, Environment and Melanoma Study, 1,223 European-origin participants had their incident invasive primary melanomas screened for BRAF/NRAS mutations and germline DNA genotyped for 47 single-nucleotide polymorphisms identified as low-penetrant melanoma-risk variants. We used multinomial logistic regression to simultaneously examine each single-nucleotide polymorphism's relationship to BRAF V600E, BRAF V600K, BRAF other, and NRAS+ relative to BRAF-/NRAS- melanoma adjusted for study features. IRF4 rs12203592*T was associated with BRAF V600E (odds ratio [OR] = 0.59, 95% confidence interval [CI] = 0.43-0.79) and V600K (OR = 0.65, 95% CI = 0.41-1.03), but not BRAF other or NRAS+ melanoma. A global test of etiologic heterogeneity (Pglobal = 0.001) passed false discovery (Pglobal = 0.0026). PLA2G6 rs132985*T was associated with BRAF V600E (OR = 1.32, 95% CI = 1.05-1.67) and BRAF other (OR = 1.82, 95% CI = 1.11-2.98), but not BRAF V600K or NRAS+ melanoma. The test for etiologic heterogeneity (Pglobal) was 0.005. The IRF4 rs12203592 associations were slightly attenuated after adjustment for melanoma-risk phenotypes. The PLA2G6 rs132985 associations were independent of phenotypes. IRF4 and PLA2G6 inherited genotypes may influence melanoma BRAF/NRAS subtype development.
引用
- Thomas NE, Edmiston SN, Orlow I, et al. Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes. J Invest Dermatol. 2018. PMID: 29753029. doi:10.1016/j.jid.2018.04.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。